The price-to-earnings ratio for Boston Scientific Corp (NYSE: BSX) is above average at 74.97x. The 36-month beta value for BSX is also noteworthy at 0.69. There are mixed opinions on the stock, with 23 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for BSX is 1.47B, and at present, short sellers hold a 0.98% of that float. The average trading volume of BSX on April 28, 2025 was 8.50M shares.
BSX) stock’s latest price update
The stock of Boston Scientific Corp (NYSE: BSX) has increased by 0.31 when compared to last closing price of 101.90.Despite this, the company has seen a gain of 9.23% in its stock price over the last five trading days. zacks.com reported 2025-04-28 that Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock’s price, do they really matter?
BSX’s Market Performance
Boston Scientific Corp (BSX) has experienced a 9.23% rise in stock performance for the past week, with a 1.41% rise in the past month, and a -0.05% drop in the past quarter. The volatility ratio for the week is 2.64%, and the volatility levels for the past 30 days are at 3.81% for BSX. The simple moving average for the past 20 days is 6.08% for BSX’s stock, with a 13.50% simple moving average for the past 200 days.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Needham repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Needham is $113 based on the research report published on April 16, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see BSX reach a price target of $108. The rating they have provided for BSX stocks is “Buy” according to the report published on January 10th, 2025.
BSX Trading at 2.91% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.62% of loss for the given period.
Volatility was left at 3.81%, however, over the last 30 days, the volatility rate increased by 2.64%, as shares surge +3.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.36% lower at present.
During the last 5 trading sessions, BSX rose by +9.61%, which changed the moving average for the period of 200-days by +33.02% in comparison to the 20-day moving average, which settled at $96.38. In addition, Boston Scientific Corp saw 14.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Brown Vance R, who sale 4,826 shares at the price of $95.09 back on Apr 21 ’25. After this action, Brown Vance R now owns 36,193 shares of Boston Scientific Corp, valued at $458,904 using the latest closing price.
VANCE BROWN, the Officer of Boston Scientific Corp, proposed sale 4,826 shares at $95.09 during a trade that took place back on Apr 21 ’25, which means that VANCE BROWN is holding shares at $458,904 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.67 for the gross margin
The net margin for Boston Scientific Corp stands at 0.12. The total capital return value is set at 0.09. Equity return is now at value 9.03, with 4.97 for asset returns.
Based on Boston Scientific Corp (BSX), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is 19.97.
Currently, EBITDA for the company is 2.6 billion with net debt to EBITDA at 2.82. When we switch over and look at the enterprise to sales, we see a ratio of 9.23. The receivables turnover for the company is 6.86for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In summary, Boston Scientific Corp (BSX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
